CPIX News and Press, Cumberland Pharmaceuticals Inc. From 05/15/23

CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS PR Newswire Caldolor ® is the only injectable non-opioid approved for treating pain in infants NASHV...

2023-05-09 16:54:43 ET Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): Q1 Non-GAAP EPS of $0.11. Revenue of $9.2M (-17.9% Y/Y). For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of $0.11, revenue of $9.2M

Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update PR Newswire NASHVILLE, Tenn. , May 9, 2023 /PRNewswire/ -- Cumberland P...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release th...

2023-03-07 22:47:02 ET Cumberland Pharmaceuticals Inc. (CPIX) Q4 2022 Earnings Conference Call March 07, 2023, 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development Joh...

2023-03-07 16:25:41 ET Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): FY GAAP EPS of -$0.17. Revenue of $9.12M (+9.9% Y/Y). For further details see: Cumberland Pharmaceuticals GAAP EPS of -$0.17, revenue of $9.12M

CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022 PR Newswire 2022 highlights include its acquisition of Sancuso ® and move to new headquarters NASHVILLE, Tenn. , March 7, 2023 /PRNewswire/ -- Cumberland Pharmaceutica...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceuticals company, announced today that it will release its an...

Cumberland Pharmaceuticals, Inc. (CPIX) Q3 2022 Earnings Conference Call November 08, 2022, 16:30 ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Founder, Chairman, President & CEO John Hamm - Senior Director of Finance ...

Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): Q3 Non-GAAP EPS of $0.10. Revenue of $11.41M (+40.9% Y/Y). Shares +6% . For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of $0.10, revenue of $11.41M